MedPath
Found 3 clinical trials|View Analysis
Sort by:

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Phase 2
Not yet recruiting
Conditions
Advanced Pancreatic Cancer
Interventions
Radiation: Stereotactic body radiation
Drug: Nimotuzumab
Drug: mono-chemotherapy
First Posted Date
2024-05-20
Last Posted Date
2024-05-20
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
73
Registration Number
NCT06422156

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Phase 2
Conditions
Intrahepatic Cholangiocarcinoma by AJCC V8 Stage
Interventions
Drug: Combination therapy
Drug: Mono-chemotherapy
First Posted Date
2020-06-04
Last Posted Date
2020-06-04
Lead Sponsor
Zhejiang University
Target Recruit Count
120
Registration Number
NCT04413734
Locations
🇨🇳

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Phase 3
Terminated
Conditions
Breast Cancer
Interventions
Drug: Ribociclib
Other: Mono-chemotherapy
Other: Endocrine-Therapy
First Posted Date
2019-04-05
Last Posted Date
2021-06-16
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
25
Registration Number
NCT03905343
Locations
🇧🇪

Grand Hôpital de Charleroi, Charleroi, Belgium

🇧🇪

Jessa Ziekenhuis, Hasselt, Belgium

🇨🇭

Brustzentrum Basel - Praxis für ambulante Tumortherapie, Basel, Switzerland

and more 31 locations
© Copyright 2025. All Rights Reserved by MedPath